Impel Pharmaceuticals (NASDAQ:
IMPL), a commercial-stage pharmaceutical
company developing transformative therapies for people suffering
from diseases with high unmet medical needs, today reported
financial results for the third quarter ended September 30, 2022
and provided a corporate update.
“This quarter represents a milestone for Impel
as we completed the first full year of Trudhesa® marketing and
sales, generating over 42,000 prescriptions at the end of
September,” said Adrian Adams, Chairman of the Board and Chief
Executive Officer of Impel Pharmaceuticals. “Trudhesa continues to
show robust growth and momentum and has captured approximately a 5%
market share of acute branded prescriptions among prescribers after
only one year in the market.”
Adams added, “We are also encouraged with the
results that we’ve seen from the additional sales force added
towards the end of July of this year. As expected, the expansion
has led to efficiencies among both new and existing sales
representatives and has already had a positive impact on all
leading performance indicators. We have increased Trudhesa
prescribers by 30 percent and increased new patients by 58 percent
since Q2 and will continue to have a strong focus on disciplined
execution. At the same time we are actively assessing both
financing and strategic opportunities. ”
Recent Corporate
HighlightsTrudhesa® (Dihydroergotamine Mesylate)
Nasal Spray (0.725 Mg Per Spray)
- To-date, Trudhesa continues a strong trajectory with more than
48,600 prescriptions generated since launch Based on third-party
data, it is estimated that at the end of September Trudhesa
accounts for 5.2 percent of branded acute migraine prescriptions
(nTRx) among prescribers.
- In July of this year, Impel expanded its sales force by 50
percent, from 60 to 90 sales professionals, to further capitalize
on prescription momentum and the large business opportunity. New
Trudhesa prescriptions increased by 45 percent from Q2 to Q3 2022
driven by an expanded, more efficient salesforce. Additionally, the
existing (n=60) and new (n=30) sales representatives increased
monthly new patients starts by 56 percent and 74 percent,
respectively, from July 2022 to October 2022 for a total increase
in monthly new patient starts of 58 percent during this time
period.
- Reimbursement of all shipments is over 50 percent for the
entire year and 58 percent for the third quarter 2022. Refill rates
have remained consistently high with 63 percent at the end of the
third quarter 2022.
- Company will have a presence at the American Headache Society
(AHS) Scottsdale Headache Symposium® taking place in
Scottsdale, Arizona, November 17-20, 2022.
Clinical Developments
- In July 2022, the first patient was
dosed in a Phase 2a proof-of-concept study (the CALM 201 Study) to
advance its combination product candidate, INP105, an intranasal
olanzapine product (a widely used atypical, second-generation
antipsychotic) being developed as an acute treatment for agitation
in persons with autism spectrum disorder using Impel’s POD
technology. Results from this trial are expected in Q2 2023.
- In September 2022, Impel published
a manuscript in the Journal of Aerosol Medicine and Pulmonary Drug
Delivery, that showed the upper nasal space is an attractive
alternative route (to oral medications) of drug delivery. The paper
evaluated the safety of the novel technology powering Trudhesa,
Precision Olfactory Delivery (POD®), a device that delivers drug
specifically to the upper nasal space. Results from clinical studies
of Trudhesa demonstrated that the POD technology may have the
potential to overcome the limitations of traditional nasal delivery
systems, while utilizing the nasal delivery benefits of
gastrointestinal tract avoidance, rapid onset, patient convenience
and ease of use.
- In October 2022, Impel published a
comprehensive review of both published and previously unpublished
preclinical data outlining the development and optimization of
INP105 using Impel’s POD® technology. These findings have been
published in the October issue of the Medical Research Archives, an
international scientific peer-reviewed journal publishing articles
in all disciplines of medicine.
Financial Results for Third Quarter
2022
- Net Product
Revenue: The Company’s net revenue from sales of
Trudhesa was $3.1 million for the third quarter 2022. As initial
shipments of Trudhesa were sent to specialty pharmacies in late
September 2021 ahead of the October commercial launch, there were
no product revenues for the same period of 2021.
- Research and Development
(R&D) Expenses: R&D expenses were $3.2 million for
the third quarter 2022 compared with $5.9 million for the same
period of 2021. The decrease in R&D spending was primarily due
to a reduction in Trudhesa clinical expenses as the Phase 3 STOP
301 study was closed, and partially offset by an increase in spend
for the clinical development of INP105.
- Selling, General and
Administrative (SG&A) Expenses: SG&A expenses were
$19.7 million for the third quarter 2022, compared with $16.3
million for the same period of 2021. The increase in SG&A
spending was due primarily due to the continued ramp up in spending
to support the commercial, sales and marketing activity in support
of the Trudhesa launch.
- GAAP Net Loss: Net
losses for the third quarter 2022 were $31.8 million or $1.34 per
common share. This is compared to net losses of $25 million or
$1.24 per common share for the same period in 2021.
- Non-GAAP Net Loss Per
Share: Non-GAAP Net Loss Per Share for the third quarter
2022 were $1.34 compared to a Non-GAAP Net Loss Per Share of $1.24
for the same periods in 2021. Non-GAAP Pro Forma Net Loss Per Share
gives effect to our reverse stock split, the shares of common stock
issued in our April 2021 IPO, shares exchanged for previously
issued and outstanding stock warrants of Impel, and the conversion
of our convertible preferred stock and our convertible notes into
shares of common stock as if such conversions occurred at the
beginning of each period presented. Non-GAAP Net Loss Per Share
excludes the change in fair value of the convertible notes and
interest expense on our convertible notes, the effect of accretion
on our redeemable convertible preferred stock and the change in
fair value of our redeemable convertible preferred stock
warrants, all of which converted to shares of common stock in our
April 2021 IPO. Please refer to the section in this press release
titled "Reconciliation of GAAP and Non-GAAP Results" for
details.
- Cash on hand: As
of September 30, 2022, Impel had approximately $79.9 million in
cash and cash equivalents.
Conference Call Information
Impel Pharmaceuticals’ Executive Management will
host a live conference call and webcast at 8:30 a.m. ET today to
discuss the third quarter 2022 financial results and provide a
corporate update. To access the live conference call, please
register using the conference link: Conference Registration
(vevent.com). A live webcast of the event will be available on the
Investors section of the Impel Pharmaceuticals website at
https://investors.impelpharma.com/. A replay of the webcast and
accompanying slides will be available on the Impel Pharmaceuticals
website following the event
Non-GAAP Financial MeasuresWe
have provided in this press release certain financial information
that has not been prepared in accordance with generally accepted
accounting principles in the United States (“GAAP”). Our management
uses these non-GAAP financial measures internally in analyzing our
financial results and believes that use of these non-GAAP financial
measures is useful to investors as an additional tool to evaluate
ongoing operating results and trends and in comparing our financial
results with other companies in our industry, many of which present
similar non-GAAP financial measures. Non-GAAP financial measures
are not meant to be considered in isolation or as a substitute for
comparable financial measures prepared in accordance with GAAP and
should be read only in conjunction with our consolidated financial
statements prepared in accordance with GAAP. A reconciliation of
our historical non-GAAP financial measures to the most directly
comparable GAAP measures has been provided in the financial
statement tables included in this press release, and investors are
encouraged to review these reconciliations.
About Impel
PharmaceuticalsImpel Pharmaceuticals is a commercial-stage
pharmaceutical company developing transformative therapies for
people suffering from diseases with high unmet medical needs, with
an initial focus on diseases of the central nervous system. Impel
offers and is developing treatments that pair its proprietary POD®
technology with well-established therapeutics. In addition to
Trudhesa® nasal spray, which is approved in the U.S. for the acute
treatment of migraine with or without aura in adults, Impel is also
developing INP105 for the acute treatment of agitation and
aggression in patients with autism.
About Impel’s Precision Olfactory
Delivery (POD®) Technology:Impel’s proprietary POD®
technology is able to deliver a range of therapeutic molecules and
formulations into the vascular-rich upper nasal space, believed to
be a gateway for unlocking the previously unrealized full potential
of these molecules. By delivering predictable doses of drug
directly to the upper nasal space, Impel’s precision performance
technology has the goal of enabling increased and consistent
absorption of drug, overriding the high variability associated with
other nasal delivery systems, yet without the need for an
injection. While an ideal target for drug administration, to date
no technology has been able to consistently deliver drugs to the
upper nasal space. By utilizing this route of administration, Impel
Pharmaceuticals has been able to demonstrate blood concentration
levels for its investigational therapies that are comparable to
intramuscular (IM) administration and can even reach intravenous
(IV)-like systemic levels quickly, which could transform the
treatment landscape for central nervous system (CNS) and other
disorders. Importantly, the POD technology offers
propellant-enabled delivery of dry powder and liquid formulations
that eliminates the need for coordination of breathing, allowing
for self- or caregiver-administration in a manner that may improve
patient outcome, comfort, and potentially, compliance.
About Trudhesa®
IndicationTrudhesa® is used to treat an active
migraine headache with or without aura in adults. Do not use
Trudhesa to prevent migraine when you have no symptoms. It is not
known if Trudhesa is safe and effective in children.
Important Safety
Information
Serious or potentially life-threatening reductions in blood flow to
the brain or extremities due to interactions between
dihydroergotamine (the active ingredient in Trudhesa) and strong
CYP3A4 inhibitors (such as protease inhibitors and macrolide
antibiotics) have been reported rarely. As a result, these
medications should not be taken together. |
Do not use Trudhesa if you:
- Have any disease affecting your
heart, arteries, or blood circulation.
- Are taking certain anti-HIV
medications known as protease inhibitors (such as ritonavir or
nelfinavir).
- Are taking a macrolide antibiotic
such as clarithromycin or erythromycin.
- Are taking certain antifungals such
as ketoconazole or itraconazole.
- Have taken certain medications such
as triptans or ergot-type medications for the treatment or
prevention of migraine within the last 24 hours.
- Have taken any medications that
constrict your blood vessels or raise your blood pressure.
- Have severe liver or kidney
disease.
- Are allergic to ergotamine or
dihydroergotamine.
Before taking Trudhesa, tell your doctor
if:
- You have high blood pressure, chest
pain, shortness of breath, heart disease; or risk factors for heart
disease (such as high blood pressure, high cholesterol, obesity,
diabetes, smoking, strong family history of heart disease or you
are postmenopausal, or male over 40); or problems with blood
circulation in your arms, legs, fingers, or toes.
- You have or had any disease of the
liver or kidney.
- You are taking any prescription or
over-the-counter medications, including vitamins or herbal
supplements.
- You are pregnant, planning to
become pregnant or are nursing, or have ever stopped medication due
to an allergy or bad reaction.
- This headache is different from
your usual migraine attacks.
The use of Trudhesa should not exceed dosing
guidelines and should not be used on a daily basis. Serious cardiac
(heart) events, including some that have been fatal, have occurred
following the use of dihydroergotamine mesylate, particularly with
dihydroergotamine for injection, but are extremely rare.
You may experience some nasal congestion or
irritation, altered sense of taste, sore throat, nausea, vomiting,
dizziness, and fatigue after using Trudhesa. Contact your doctor
immediately if you experience:
- Numbness or tingling in your
fingers and toes
- Severe tightness, pain, pressure,
heaviness, or discomfort in your chest
- Muscle pain or cramps in your arms
or legs
- Cold feeling or color changes in
one or both legs or feet
- Sudden weakness
- Slurred speech
- Swelling or itching
The risk information provided here is not
comprehensive. To learn more, talk about Trudhesa with your
healthcare provider or pharmacist. The FDA-approved product
labeling can be found at www.Trudhesa.com or 1-800-555-DRUG. You
can also call 1-833-TRUDHESA (1-833-878-3437) for additional
information.
About INP105:INP105 is an upper
nasal formulation of olanzapine administered using Impel’s novel
POD® technology and being developed for the potential treatment of
agitation and aggression associated with autism spectrum disorder.
The POD® is a novel, simple-to-use device designed to deliver
consistent and predictable doses of drug. INP105 delivers
olanzapine to the richly vascularized upper nasal space to offer
rapid, consistent, and optimized bioavailability that can be
administered by the patient or a caregiver. Olanzapine is the most
used treatment for acute agitation, but its use is limited to
intramuscular injection and in a hospital setting. INP105 is
intended to be a preferred choice for the safe and rapid treatment
of acute agitation and because it is designed to be non-invasive,
it has the potential to expand the treatment setting beyond the
emergency room, such as inpatient treatment or community care
facilities and the patient’s home.
Cautionary Note on Forward-Looking
StatementsThis press release contains “forward-looking”
statements within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including,
but not limited to, the potential clinical benefits of Trudhesa®,
the market opportunities of Trudhesa within the migraine market,
the speed of uptake and market growth of Trudhesa, the
effectiveness of the Trudhesa sales force, the timing of
announcements of clinical results and clinical development
activities of Impel’s product candidates, and Impel’s cash runway.
Forward-looking statements can be identified by words such as:
“believe,” “may,” “will,” “potentially,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “would,” “project,” “plan,”
“expect” or the negative or plural of these words or similar
expressions. These statements are subject to numerous risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including but not limited to,
Impel’s ability to maintain regulatory approval of Trudhesa, its
ability to execute its commercialization strategy for Trudhesa, its
ability to develop, manufacture and commercialize its other product
candidates including plans for future development of its POD®
devices and plans to address additional indications for which Impel
may pursue regulatory approval, whether results of preclinical
studies or clinical trials will be indicative of the results of
future trials, and the effects of COVID-19 on its clinical programs
and business operations. Many of these risks are described in
greater detail in Impel’s filings with the Securities and Exchange
Commission. Any forward-looking statements in this press release
speak only as of the date of this press release. Impel assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Impel, POD and the Impel logo are trademarks of
Impel Pharmaceuticals Inc. To learn more about Impel
Pharmaceuticals, please visit our website at
https://impelpharma.com.
|
|
|
|
|
|
|
|
IMPEL
PHARMACEUTICALS INC. Condensed Consolidated Balance Sheet (In
thousands, except share and per share data) |
|
|
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
December 31, 2021 |
|
|
Assets |
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
79,731 |
|
|
$ |
88,212 |
|
|
|
Trade receivables, net |
|
|
6,129 |
|
|
|
1,352 |
|
|
|
Inventory |
|
|
8,622 |
|
|
|
2,824 |
|
|
|
Prepaid expenses and other current assets |
|
|
4,794 |
|
|
|
2,188 |
|
|
|
Total
current assets |
|
|
99,276 |
|
|
|
94,576 |
|
|
|
Property and
equipment, net |
|
|
2,776 |
|
|
|
3,149 |
|
|
|
Operating
lease right-of-use assets |
|
|
2,933 |
|
|
|
— |
|
|
|
Other
assets |
|
|
187 |
|
|
|
187 |
|
|
|
Total assets |
|
$ |
105,172 |
|
|
$ |
97,912 |
|
|
|
Liabilities and stockholders’ (deficit)
equity |
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
4,751 |
|
|
$ |
6,367 |
|
|
|
Accrued liabilities |
|
|
11,743 |
|
|
|
8,950 |
|
|
|
Current portion of deferred royalty obligation |
|
|
1,765 |
|
|
|
— |
|
|
|
Current portion of operating lease liability |
|
|
1,346 |
|
|
|
— |
|
|
|
Common stock warrant liability |
|
|
358 |
|
|
|
637 |
|
|
|
Total
current liabilities |
|
|
19,963 |
|
|
|
15,954 |
|
|
|
Operating lease liability, net of current portion |
|
|
1,584 |
|
|
|
— |
|
|
|
Derivative liability |
|
|
1,890 |
|
|
|
— |
|
|
|
Deferred royalty obligation, net of current portion |
|
|
56,662 |
|
|
|
— |
|
|
|
Long-term debt |
|
|
47,362 |
|
|
|
29,450 |
|
|
|
Total liabilities |
|
|
127,461 |
|
|
|
45,404 |
|
|
|
Commitments
and contingencies |
|
|
|
|
|
|
Stockholders’ (deficit) equity: |
|
|
|
|
|
|
Preferred stock, $0.001 par value; 10,000,000 shares authorized:
none issued |
|
|
— |
|
|
|
— |
|
|
|
Common stock, $0.001 par value; 300,000,000 shares authorized;
23,739,313 and 23,037,298 shares issued and outstanding at
September 30, 2022 and December 31, 2021, respectively |
|
|
24 |
|
|
|
23 |
|
|
|
Additional paid-in capital |
|
|
275,756 |
|
|
|
267,283 |
|
|
|
Accumulated deficit |
|
|
(298,069 |
) |
|
|
(214,798 |
) |
|
|
Total
stockholders’ (deficit) equity |
|
|
(22,289 |
) |
|
|
52,508 |
|
|
|
Total liabilities and stockholders’ (deficit)
equity |
|
$ |
105,172 |
|
|
$ |
97,912 |
|
|
|
|
|
|
|
|
|
|
Impel
Pharmaceuticals Inc.Condensed Consolidated Statement of Operations
and Comprehensive Loss(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months EndedSeptember 30, |
|
For the Nine Months EndedSeptember 30, |
|
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
Product revenue, net |
|
$ |
3,082 |
|
|
$ |
91 |
|
|
$ |
7,644 |
|
|
$ |
91 |
|
|
|
Cost of goods sold |
|
|
1,508 |
|
|
|
250 |
|
|
|
4,277 |
|
|
|
250 |
|
|
|
Gross profit |
|
|
1,574 |
|
|
|
(159 |
) |
|
|
3,367 |
|
|
|
(159 |
) |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
3,155 |
|
|
|
5,929 |
|
|
|
10,756 |
|
|
|
16,103 |
|
|
|
Selling, general and administrative |
|
|
19,659 |
|
|
|
16,338 |
|
|
|
57,553 |
|
|
|
30,971 |
|
|
|
Total operating expenses |
|
|
22,814 |
|
|
|
22,267 |
|
|
|
68,309 |
|
|
|
47,074 |
|
|
|
Loss from operations |
|
|
(21,240 |
) |
|
|
(22,426 |
) |
|
|
(64,942 |
) |
|
|
(47,233 |
) |
|
|
Other income (expense), net : |
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net |
|
|
(3,192 |
) |
|
|
(2,420 |
) |
|
|
(11,069 |
) |
|
|
(3,471 |
) |
|
|
Other income (expense), net |
|
|
(6,665 |
) |
|
|
(175 |
) |
|
|
(7,260 |
) |
|
|
(1,090 |
) |
|
|
Total other income (expense), net |
|
|
(9,857 |
) |
|
|
(2,595 |
) |
|
|
(18,329 |
) |
|
|
(4,561 |
) |
|
|
Loss before income taxes |
|
|
(31,097 |
) |
|
|
(25,021 |
) |
|
|
(83,271 |
) |
|
|
(51,794 |
) |
|
|
Provision for income taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
Net loss and comprehensive loss |
|
$ |
(31,097 |
) |
|
$ |
(25,021 |
) |
|
$ |
(83,271 |
) |
|
$ |
(51,794 |
) |
|
|
Accretion on redeemable convertible preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
129 |
|
|
|
Net loss attributable to common stockholders |
|
$ |
(31,097 |
) |
|
$ |
(25,021 |
) |
|
$ |
(83,271 |
) |
|
$ |
(51,923 |
) |
|
|
Net loss per share attributable to common stockholders, basic and
diluted |
|
$ |
(1.31 |
) |
|
$ |
(1.24 |
) |
|
$ |
(3.57 |
) |
|
$ |
(4.42 |
) |
|
|
Weighted-average shares used in computing net loss per share
attributable to common stockholders, basic and diluted |
|
|
23,709,546 |
|
|
|
20,150,990 |
|
|
|
23,345,946 |
|
|
|
11,746,923 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impel
Pharmaceuticals Inc. Earnings Per Share (in thousands, except share
and per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
For the Nine Months Ended September 30, |
|
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
GAAP
Basic and Diluted EPS |
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
Net loss and
comprehensive loss |
|
$ |
(31,097 |
) |
|
$ |
(25,021 |
) |
|
$ |
(83,271 |
) |
|
$ |
(51,794 |
) |
|
|
Add:
Accretion of preferred stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(129 |
) |
|
|
Net loss
attributable to common shareholders |
|
$ |
(31,097 |
) |
|
$ |
(25,021 |
) |
|
$ |
(83,271 |
) |
|
$ |
(51,923 |
) |
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares shares outstanding, basic and
diluted |
|
|
23,709,546 |
|
|
|
20,150,990 |
|
|
|
23,345,946 |
|
|
|
11,746,923 |
|
|
|
Net loss per
share attributable to common shareholders, basic and diluted |
|
$ |
(1.31 |
) |
|
$ |
(1.24 |
) |
|
$ |
(3.57 |
) |
|
$ |
(4.42 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
For the Nine Months Ended September 30, |
|
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
Non-GAAP loss per share information: |
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
Historical
net loss attributable to common shareholders |
|
$ |
(31,097 |
) |
|
$ |
(25,021 |
) |
|
$ |
(83,271 |
) |
|
$ |
(51,923 |
) |
|
|
Accretion of
preferred stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
129 |
|
|
|
Change in
fair value of convertible notes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
839 |
|
|
|
Change in
fair value of redeemable convertible preferred stock warrant
liabilities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
222 |
|
|
|
Interest
expense on convertible notes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
55 |
|
|
|
Non-GAAP pro
forma net loss attributable to common stockholders |
|
$ |
(31,097 |
) |
|
$ |
(25,021 |
) |
|
$ |
(83,271 |
) |
|
$ |
(50,678 |
) |
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
Common
shares outstanding: |
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
23,709,546 |
|
|
|
20,150,990 |
|
|
|
23,345,946 |
|
|
|
11,746,923 |
|
|
|
Shares issued in IPO |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,266,179 |
|
|
|
Common shares issued upon conversion of preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,356,311 |
|
|
|
Automatic exchange of Avenue warrant |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
45,747 |
|
|
|
Issuance of shares of common stock pursuant to the cash and net
exercise of warrants |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
26,138 |
|
|
|
Shares issued upon conversion of convertible notes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
237,772 |
|
|
|
Weighted-average number of common shares outstanding used to
compute pro forma net loss per share, as adjusted, basic and
diluted |
|
|
23,709,546 |
|
|
|
20,150,990 |
|
|
|
23,345,946 |
|
|
|
19,679,070 |
|
|
|
Pro forma
net loss per share attributable to common shareholders, basic and
diluted |
|
$ |
(1.31 |
) |
|
$ |
(1.24 |
) |
|
$ |
(3.57 |
) |
|
$ |
(2.58 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Contact: |
|
Investor Relations: |
Media Relations: |
Christina Tartaglia |
Melyssa Weible |
Stern Investor Relations |
Elixir Health Public Relations |
Phone: (1) 212-362-1200 |
Phone: (1) 201-723-5805 |
Email: christina.tartaglia@sternir.com |
Email: mweible@elixirhealthpr.com |
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Apr 2023 to Apr 2024